FDA-Approved Test for Plavix May Be Pointless and a Waste of Money (ContributorNetwork)
ContributorNetwork – COMMENTARY | Is the FDA recommending genetic tests that waste money? A new study published in the Dec. 28 issue of the Journal of the American Medical Association reveals that an FDA approved test may actually be pointless. CYP2C19 genotype testing may not be an effective method for determining a prescription. Although this genetic test has been recommended for patients who may not benefit from the blood thinner clopidogrel or Plavix, the paper published in JAMA points out that the CYP2C19 genotype should not be used for cardiovascular diseases. I am not surprised by the findings of the recent study because the FDA has issued premature warnings and supported wrong data in the past.
